Soooo..... is this a move to support a good quarterly and maintain momentum, or a move to prop up a poor quarterly in the hope to generate some momentum...?? R.T.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%